Article

Digital Mammography Combined with Tomosynthesis Improves Breast Cancer Screening

Improved cancer detection rates and a reduced recall rates can be enhanced.

Researchers found a link between the combination of digital mammography and a form of imaging with an increase in cancer detection rates and a reduction in recall rates for breast cancer patients.

A study published in JAMA evaluated the screening performance of digital mammography in combination with tomosynthesis compared with digital mammography alone in women with different levels of breast density.

Data was taken from screening performance metrics, reported for 12 months using digital mammography alone and the start of tomosynthesis from 13 US institutions.

The data included 452,350 examinations, 278,906 of which were digital mammographies alone, while 173,414 were digital mammographies plus tomosynthesis. There were 2157 cancers that were diagnosed. The results of the study showed there was an association between tomosynthesis plus digital mammography and increased cancer detections rates and decreased recall rates for dense and nondense breast tissue.

“These combined gains were largest for women with heterogeneously dense breasts, potentially addressing limitations in cancer detection seen with digital mammography alone in this group, but were not significant in women with extremely dense breasts,” the authors said.

Researchers noted that of women classified as having dense breast tissue, a majority have heterogeneously dense breasts. This suggests mandating caution when drawing conclusions on the performance of tomosynthesis for women with extremely dense breasts.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards